Real-World Clinical Use of Esaxerenone in Hypertensive Patients

Abstract

Esaxerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), has emerged as a promising therapeutic option for hypertension, especially in cases resistant to conventional regimens. This review comprehensively examines the real-world clinical application of esaxerenone, integrating recent evidence, mechanistic insights, and guideline-based recommendations to aid clinicians in optimizing blood pressure control and minimizing cardiorenal risks in hypertensive patients. Focus is placed on epidemiological context, pathophysiological rationale, patient selection, efficacy, safety, and practical management strategies, including emerging data and future perspectives.

Introduction

Hypertension remains a primary modifiable risk factor for cardiovascular morbidity and mortality worldwide, despite advances in pharmacotherapy. Achieving optimal blood pressure (BP) control is often challenging, with a significant subset of patients displaying resistance to standard antihypertensive regimens. The renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in hypertension pathogenesis, and excessive mineralocorticoid receptor (MR) activation contributes to vascular and renal dysfunction. Esaxerenone, a potent and selective non-steroidal MRA, offers a novel approach to targeting aldosterone-mediated pathology with potential for improved tolerability and efficacy compared to traditional agents such as spironolactone and eplerenone. This review synthesizes current literature to inform clinicians of the real-world utilization, benefits, and challenges of esaxerenone in hypertensive populations.

Epidemiology / Disease Burden

Hypertension affects over 1.3 billion individuals globally, with rising prevalence in both developed and developing regions. Despite widespread awareness and treatment, only 20-40% of patients achieve adequate BP control. Resistant hypertension, defined as uncontrolled BP despite optimal doses of three antihypertensive drugs, including a diuretic, affects up to 10-20% of treated hypertensives. This population exhibits markedly increased risks for stroke, myocardial infarction, heart failure, and chronic kidney disease. The search for novel pharmacological interventions is driven by the substantial residual risk and the need for agents with improved efficacy and safety profiles.

Pathophysiology

The MR, predominantly expressed in renal tubular cells, mediates aldosterone-induced sodium retention and potassium excretion, contributing to intravascular volume expansion and hypertension. Beyond the kidneys, MR activation in cardiovascular tissues promotes inflammation, fibrosis, and endothelial dysfunction—mechanisms central to target organ damage. Traditional steroidal MRAs, though effective, are limited by off-target effects and hyperkalemia risk. Esaxerenone, with high selectivity for MR and minimal interaction with androgen/progesterone receptors, offers a mechanistically rational alternative for modulating aldosterone-driven pathology in hypertension.

Risk Factors

Risk factors for hypertension and, by extension, candidates for MRA therapy, include advanced age, obesity, high salt intake, metabolic syndrome, diabetes mellitus, chronic kidney disease (CKD), and genetic predisposition. Secondary hyperaldosteronism, primary aldosteronism, and resistant hypertension are scenarios where aldosterone blockade is particularly beneficial. Recognizing patient subgroups with heightened aldosterone activity is crucial for personalized antihypertensive strategies.

Clinical Features

Hypertensive patients with aldosterone excess may present with persistent elevation of systolic and/or diastolic BP, often refractory to standard triple therapy. Clinical suspicion should be heightened in those with hypokalemia, left ventricular hypertrophy, albuminuria, or a history of cardiovascular events despite treatment. Esaxerenone’s efficacy in reducing BP is supported by its ability to attenuate both volume-dependent and tissue-mediated MR effects, translating to improved cardiovascular and renal outcomes in real-world cohorts.

Diagnosis

Diagnosis of hypertension remains predicated on repeated BP measurements and assessment of end-organ damage. In suspected primary aldosteronism or resistant hypertension, evaluation includes plasma aldosterone-renin ratio, confirmatory suppression testing, and assessment of serum electrolytes. Identification of patients likely to benefit from MR antagonism, such as those with aldosterone-mediated hypertension or evidence of RAAS activation, is essential for targeted therapy. Real-world studies demonstrate that esaxerenone is particularly effective in these subgroups, with favorable tolerability profiles.

Treatment & Management

Management of hypertension requires a multifaceted approach, including lifestyle modification and pharmacotherapy. Esaxerenone is indicated for essential hypertension and has shown robust BP-lowering effects as monotherapy and adjunctive therapy. In clinical practice, the starting dose is typically 2.5 mg/day, titratable to 5 mg/day based on response and tolerability. Esaxerenone’s selectivity reduces the incidence of gynecomastia and sexual dysfunction seen with spironolactone, while its pharmacokinetics support once-daily dosing. Renal function and serum potassium should be monitored, particularly in patients with CKD or concomitant RAAS inhibitors. Dose adjustments or alternate therapies may be warranted in those with significant hyperkalemia.

Recent Advances / Emerging Therapies

Recent Phase III clinical trials and real-world observational studies have confirmed the efficacy and safety of esaxerenone in diverse hypertensive populations, including elderly patients and those with diabetes or CKD. Notably, esaxerenone has demonstrated superior albuminuria reduction compared to placebo and eplerenone, suggesting renal protective effects beyond BP lowering. Ongoing studies are exploring its utility in heart failure with preserved ejection fraction (HFpEF) and its role in primary aldosteronism. Combination regimens with SGLT2 inhibitors or novel antihypertensives represent promising avenues for further improving outcomes in high-risk cohorts.

Guideline Recommendations

Updated hypertension guidelines from Japan, where esaxerenone is currently approved, endorse its use as both first-line and add-on therapy in patients with essential or resistant hypertension. International guidelines recognize the class effect of MRAs in resistant hypertension and secondary aldosteronism, with esaxerenone’s improved tolerability profile likely to expand its adoption pending broader regulatory approval. Expert consensus supports individualized therapy based on comorbidities, risk stratification, and close biochemical monitoring to maximize benefits while minimizing adverse events.

Conclusion

Esaxerenone represents a significant advancement in the management of hypertension, offering clinicians a selective, effective, and well-tolerated option for patients inadequately controlled on standard therapies or those with aldosterone-mediated pathology. Real-world data affirm its BP-lowering and renal protective effects, with an acceptable safety profile. Ongoing research will further define its place in therapy, particularly in complex and high-risk patient populations. Integration of esaxerenone into clinical practice, guided by emerging evidence and individualized risk assessment, has the potential to improve cardiovascular and renal outcomes in hypertensive patients.